Indeed, prior studies using this cutoff have demonstrated limited clinical significance of sTIL status for predicting neoadjuvant response or oncologic outcomes in patients with ER + HER2- breast cancer compared with other subtypes [17, 38, 39]. The gene discussed is ESR1; the disease is breast carcinoma.